<DOC>
	<DOCNO>NCT00352963</DOCNO>
	<brief_summary>This study evaluate immunogenicity co-administration different combination DTPa , IPV , hepatitis B , Hib Men C vaccine first year life .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study Combined/Separate Vaccine ( ) Against Common Diseases Infants ( 2,4,6 Months Age ) .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female infant , &amp; include , 0 &amp; 7 day age time inclusion . Born normal gestation period ( 36 &amp; 42 week ) . Written inform consent obtain parent/guardian subject . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) plan use study period . Administration immunosuppressant immunemodifying drug birth . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration / plan administration vaccine foreseen study protocol period start birth end 30 day last dose except BCG vaccination give 30day period precede administration 1st dose Infanrix penta™ Infanrix hexa™ combination meningococcal C vaccine . Evidence previous intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B , meningococcal C Hib disease . Evidence previous diphtheria , tetanus , pertussis , polio , hepatitis B , meningococcal C Hib vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Open , phase 3 , Infanrix hexa™ , Hib-MenC , co-administered</keyword>
</DOC>